Recombinant Human Desmoglein-3 His-tag Protein, CF

Measured by the ability of immobilized Recombinant Human Desmoglein‑3 His-tag Protein (Catalog # 11167-DM) to support the adhesion of Caki‑2 human clear cell carcinoma epithelial cells. The ED50 for this effect is 0.750-6.00 μg/mL.

2 μg/lane of Recombinant Human Desmoglein‑3 His-tag Protein (Catalog # 11167-DM) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 57-67 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Desmoglein-3 His-tag Protein, CF Summary

• Details of Functionality: Measured by the ability of immobilized Recombinant Human Desmoglein‑3 His-tag (Catalog # 11167-DM) to support the adhesion of Caki‑2 human clear cell carcinoma epithelial cells. The ED₅₀ for this effect is 0.750-6.00 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Desmoglein-3 protein
  Glu24-Lys499, with a C-terminal 6-His tag
• Accession #: P32926.2
• N-terminal Sequence: Glu24 & Glu50
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 56 kDa & 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 57-67 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Desmoglein-3 His-tag Protein, CF

• Cadherin family member 6
• CDHF6
• CDHF6130-kD pemphigus vulgaris antigen
• desmoglein 3 (pemphigus vulgaris antigen)
• desmoglein 3
• Desmoglein3
• Desmoglein-3
• DKFZp686P23184,130 kDa pemphigus vulgaris antigen
• DSG3
• pemphigus vulgaris antigen
• PVA

Background

Desmoglein-3, also known as pemphigus vulgaris antigen (PVA), is a 130 kDa transmembrane glycoprotein that belongs to the cadherin family of calcium dependent adhesion molecules (1 - 3). Human Desmoglein-3 is synthesized with a 26 amino acid (aa) propeptide. The mature protein consists of a 566 aa extracellular domain (ECD) that contains four cadherin-like domains, a 25 aa transmembrane segment, and a 359 aa cytoplasmic domain (4). Within the ECD, human Desmoglein-3 shares 78% aa sequence identity with mouse and rat Desmoglein-3. It shares 44%, 47%, and 56% aa sequence identity with Desmoglein-1, -2, and -4 respectively. Desmoglein-3 is one of the principal components of desmosomes which form adhesive contacts between epithelial cells (1, 2). It is expressed in the basal and suprabasal layers of stratified epithelia in many tissues (4 - 6). During apoptosis, Desmoglein-3 is cleaved by caspases, plus MMP-2, and MMP-9 at sites within the cytoplasmic and extracellular regions, resulting in shortened transmembrane forms and a soluble 75 kDa ECD fragment (7, 8). The downregulation of Desmoglein-3 in oral squamous cell carcinoma correlates with metastatic potential (9). Desmoglein-3 is the target of autoantibodies in pemphigus vulgaris, a blistering skin disorder with compromised inter-keratinocyte adhesion (6, 10). Binding of these antibodies triggers Desmoglein-3 internalization and degradation by keratinocytes (10).

1. Kottke, M.D. et al. (2006) J. Cell Sci. 119:797.
2. Garrod, D.R. et al. (2002) Mol. Membr. Biol. 19:81.
3. Leckband, D. and A. Prakasam (2006) Annu. Rev. Biomed. Eng. 8:259.
4. Amagai, M. et al. (1991) Cell 67:869.
5. Silos, S.A. et al. (1996) J. Biol. Chem. 271:17504.
6. Amagai, M. et al (1996) J. Invest. Dermatol. 106:351.
7. Weiske, J. et al. (2001) J. Biol. Chem. 276:41175.
8. Cirillo, N. et al. (2007) Oral Dis. 13:341.
9. Wang, L. et al. (2007) Virchows Arch. Sept. 11 epub.
10. Calkins, C.C. et al. (2006) J. Biol. Chem. 281:7623.

Bioinformatics

• Uniprot:
  • P32926.2()